LeadBio Selected as One of China's Top 100 Emerging Medical Device Companies in 2024

Jan 02, 2025 15:28 CST Updated 15:28

LEADBIO

Medical Device Developer

Recently, the National Innovation Center for High-Performance Medical Devices (hereinafter referred to as "the NIC") released the 2024 Medical Device Industry Innovation Ecosystem Insight Assessment (hereinafter referred to as "the Assessment").LEADBIOSuccessfully Selected into the "Top 100 Innovative Index of Emerging Medical Device Companies in 2024" through Technological Innovation

This evaluation was initiated by the National Innovation Center, involving more than ten industrial chain ecosystem units from "industry, academia, research, medicine, capital, government, and management," continuing the high-standard review panel from previous sessions, with multiple senior experts and scholars from authoritative ecological organizations jointly reviewing.

The evaluation aims to discover new forces in China's medical device industry, highlight outstanding achievements in innovative medical devices, promote the rapid growth of emerging medical device companies, and commend enterprises, institutions, and individuals who have made significant contributions to the medical device field. It also helps build an innovation ecosystem for medical devices. Since its first release in 2022, the evaluation has received widespread attention within the industry and has gradually become a benchmark for innovation in the medical device industry.

The original text is sourced from @LEADBIO

About BGI Win-Win

As a venture capital institution with the industrial background of BGI Group, CGP (China Grand Pharmaceutical) possesses the dual advantages of CVC and VC institutions in terms of industrial resources and flexible decision-making mechanisms. It advocates the investment concept of "R&D-driven investment," adhering to the mapping of the industrial landscape and proactively investing along the industrial chain.Focusing on full-stage investment coverage in high-quality projects and enterprises within the bioeconomy sector, including gene technology, medical devices, cutting-edge biopharmaceuticals, and food nutrition, BGI Win-Win is committed to becoming a top-tier innovative investment management institution in the bioeconomy field. BGI Win-Win currently manages assets exceeding 2 billion RMB, with nearly 30 accumulated investments in life science projects. The core members of the Win-Win team possess over 18 years of experience in investing and project incubation within the bioeconomy sector. Historically, the team has invested in nearly 80 projects, with close to 20 IPOs and an IPO exit rate of approximately 25%.